reproxalap

Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares are advancing strongly Tuesday following the release of the results of a late-stage study of its drug candidate for allergic conjunctivitis. What Happened Aldeyra said a Phase 3 trial, dubbed ALLEVIATE, that evaluated 0.25 percent and 0.5...

Aldeyra Therapeutics Inc (NASDAQ: ALDX) develops therapies for treating inflammation, inborn errors of metabolism and other diseases related to endogenous aldehyde toxicity. What Happened The clinical-stage biotech announced a Phase 2b clinical trial that evaluated its topical ocular reproxalap in...